C. Difficile

Concomitant antibiotic (CA) use for infection treatment is a major risk factor for recurrent C difficile infection. One SHEA 2022 study examined whether fidaxomicin or vancomycin would be more beneficial for CA patients.

A study found that hospital providers who prescribe unnecessarily high rates of antibiotics are likely to continue doing so over time.

In a small retrospective study, 7 of 11 patients experienced clinical improvement.

The risk of a community-acquired C difficile infection was 7-fold higher for outpatients with antibiotic exposure.

Nearly 8 in 10 patients with recurrent C. diff. Infection were successfully treated after up to 2 doses of the microbiota-based therapy.

In a case series of 18 patients, all but 3 were cured by single-donor fecal microbiota transplantation capsule therapy.

Finch Therapeutics said it is providing information to the Food and Drug Administration to explain its testing protocols.

The product is designed to eliminate some of the drawbacks of fecal microbiota transplantation.

A new report based on samples from Texas and Kenya found significant proportions of samples from patients with CDI had nonsusceptible isolates.

The company’s investigational PF-06425090 vaccine did show benefits including decreased median infection period and no hospitalizations in the vaccinated cohort.

For the first time, a research team mapped C difficile’s outer “S-layer,” finding the dangerous bacteria’s chainmail-like shell enables it to be highly resistant.

To reduce antimicrobial resistant pathogens, nursing homes should carefully monitor their use of hospital-grade antibiotics.

While Clostridioides difficile infection (CDI) risk appeared to drop, investigators said the overall risk of infection among patients was not changed in a statistically significant way.

Hospitals with lower c difficile antibiotic usage averaged shorter length-of-stay than hospitals that prescribed more antibiotics.

A new orally delivered investigational therapy could help curb the costly and often recurring infection.

The results of the prospective study diverge from published retrospective studies.

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.

Ferring’s Microbiome Health Index is a diagnostic tool that may help distinguish a healthy gut microbiome from post-antibiotic dysbiosis, and could potentially identify debilitating illnesses such as C difficile infection

The single-center study suggested shoes are a common transmission route, but also hinted at a diverse web of transmission involving humans, animals, and the environment.

Underweight elderly pneumonia patients were more likely to contract C difficile infection.

Matt Henn, chief scientific officer at Seres Therapeutics, discusses new ways of targeting infectious diseases and antimicrobial resistant infections.

Practical considerations for the future use of novel FMT therapy for patients with recurrent Clostridioides difficile infection.

The panel reviews phase 3 data behind SER-109, another novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Experts reflect on the barriers to utilizing fecal microbiota transplantation therapy in Clostridioides difficile infection.

In a study of more than 600 elderly Japanese, being overweight was a protective factor against Clostridioides difficile infection (CDI).

COVID-19 patients were not at increased risk of Clostridium difficile infection. However, those already infected with C diff were more likely to experience severe outcomes.

The panel considers optimal therapy for recurrent CDI, particularly the role of fecal microbiota transplantation.

Centering their discussion around a patient case of CDI, experts discuss optimal therapy selection given available agents and guidelines.

Christian Lillis, co-founder and executive director of the Peggy Lillis Foundation (PLF) for C diff Education & Advocacy, says that taking care of each other is often the best way to stop the spread of infectious diseases.